106 research outputs found
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
BACKGROUND: We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC). METHODS: The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib (N=729, study 2) and an observational study of sunitinib-treated patients (N=89, study 3). RESULTS: In study 1, four SNPs showed nominally significant association (Pâ€0.05) with OS; two of these SNPs (rs1126647, rs4073) in IL8 were associated (Pâ€0.05) with OS in study 2. Because rs1126647 and rs4073 were highly correlated, only rs1126647 was evaluated in study 3, which also showed association (Pâ€0.05). In the combined data, rs1126647 was associated with OS after conservative multiple-test adjustment (P=8.8 Ă 10(-5); variant vs reference allele hazard ratio 1.32, 95% confidence interval: 1.15-1.52), without evidence for heterogeneity of effects between studies or between pazopanib- and sunitinib-treated patients. CONCLUSIONS: Variant alleles of IL8 polymorphisms are associated with poorer survival outcomes in pazopanib- or sunitinib-treated patients with aRCC. These findings provide insight in aRCC prognosis and may advance our thinking in development of new therapies
An H-alpha survey aiming at the detection of extraplanar diffuse ionized gas in halos of edge-on spiral galaxies II. The H-alpha survey atlas and catalog
In this second paper on the investigation of extraplanar diffuse ionized gas
in nearby edge-on spiral galaxies we present the actual results of the
individual galaxies of our H-alpha imaging survey. A grand total of 74 galaxies
have been studied, including the 9 galaxies of a recently studied sub-sample
(Rossa & Dettmar 2000). 40.5% of all studied galaxies reveal extraplanar
diffuse ionized gas, whereas in 59.5% of the survey galaxies no extraplanar
diffuse ionized gas could be detected. The average distances of this extended
emission above the galactic midplane range from 1-2 kpc, while individual
filaments in a few galaxies reach distances of up to |z| ~ 6 kpc. In several
cases a pervasive layer of ionized gas was detected, similar to the Reynolds
layer in our Milky Way, while other galaxies reveal only extended emission
locally. The morphology of the diffuse ionized gas is discussed for each galaxy
and is compared with observations of other important ISM constituents in the
context of the disk-halo connection, in those cases where published results
were available. Furthermore, we present the distribution of extraplanar dust in
these galaxies, based on an analysis of the unsharp-masked R-band images. The
results are compared with the distribution of the diffuse ionized gas.Comment: LaTeX, 21 pages, 7 figures, accepted for publication in A&A, figs.
22-54 are only available in electronic form and figs. 2-11 + 17-20 are also
available at http://www.astro.rub.de/jrossa/ha-surve
Strategies to design clinical studies to identify predictive biomarkers in cancer research
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological frameworkâthe DESIGN guidelinesâto standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Background:
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
Methods:
In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0â1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.
Findings:
Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4â22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4â6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16â0·34]; p<0·0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs 118 [62%]), it was 13·6 months (10·9â16·2) versus 5·4 months (5·1â5·6; 0·32 [0·24â0·42]; p<0·0001). In the intention-to-treat population, it was 10·8 months (8·3â11·4) versus 5·4 months (5·3â5·5; 0·36 [0·30â0·45]; p<0·0001). Treatment-emergent adverse events of grade 3 or higher in the safety population (372 [99%] patients in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none).
Interpretation:
Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy.
Funding:
Clovis Oncology
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
A Search for Extended Ultraviolet Disk (XUV-disk) Galaxies in the Local Universe
We have initiated a search for extended ultraviolet disk (XUV-disk) galaxies
in the local universe. Herein, we compare GALEX UV and visible--NIR images of
189 nearby (D40 Mpc) S0--Sm galaxies included in the GALEX Atlas of Nearby
Galaxies and present the first catalogue of XUV-disk galaxies. We find that
XUV-disk galaxies are surprisingly common but have varied relative (UV/optical)
extent and morphology. Type~1 objects (\ga20% incidence) have structured,
UV-bright/optically-faint emission features in the outer disk, beyond the
traditional star formation threshold. Type~2 XUV-disk galaxies (10%
incidence) exhibit an exceptionally large,
UV-bright/optically-low-surface-brightness (LSB) zone having blue
outside the effective extent of the inner, older stellar population, but not
reaching extreme galactocentric distance. If the activity occuring in XUV-disks
is episodic, a higher fraction of present-day spirals could be influenced by
such outer disk star formation. Type~1 disks are associated with spirals of all
types, whereas Type~2 XUV-disks are predominantly found in late-type spirals.
Type~2 XUV-disks are forming stars quickly enough to double their [presently
low] stellar mass in the next Gyr (assuming a constant SF rate). XUV-disk
galaxies of both types are systematically more gas-rich than the general galaxy
population. Minor external perturbation may stimulate XUV-disk incidence, at
least for Type~1 objects. XUV-disks are the most actively evolving galaxies
growing via inside-out disk formation in the current epoch, and may constitute
a segment of the galaxy population experiencing significant, continued gas
accretion from the intergalactic medium or neighboring objects.Comment: 83 pages, 16 figures, 2 tables. Appearing in the GALEX special issue
of ApJS. (A version with high quality figures and proof corrections can be
found at http://www.journals.uchicago.edu/toc/apjs/173/2
Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer
AbstractBackgroundThere is a lack of biomarkers to predict outcome with targeted therapy in metastatic clear cell renal cancer (mccRCC). This may be because dynamic molecular changes occur with therapy.ObjectiveTo explore if dynamic, targeted-therapy-driven molecular changes correlate with mccRCC outcome.Design, setting, and participantsMultiple frozen samples from primary tumours were taken from sunitinib-naĂŻve (n=22) and sunitinib-treated mccRCC patients (n=23) for protein analysis. A cohort (n=86) of paired, untreated and sunitinib/pazopanib-treated mccRCC samples was used for validation. Array comparative genomic hybridisation (CGH) analysis and RNA interference (RNAi) was used to support the findings.InterventionThree cycles of sunitinib 50mg (4 wk on, 2 wk off).Outcome measurements and statistical analysisReverse phase protein arrays (training set) and immunofluorescence automated quantitative analysis (validation set) assessed protein expression.Results and limitationsDifferential expression between sunitinib-naĂŻve and treated samples was seen in 30 of 55 proteins (p<0.05 for each). The proteins B-cell CLL/lymphoma 2 (BCL2), mutL homolog 1 (MLH1), carbonic anhydrase 9 (CA9), and mechanistic target of rapamycin (mTOR) (serine/threonine kinase) had both increased intratumoural variance and significant differential expression with therapy. The validation cohort confirmed increased CA9 expression with therapy. Multivariate analysis showed high CA9 expression after treatment was associated with longer survival (hazard ratio: 0.48; 95% confidence interval, 0.26â0.87; p=0.02). Array CGH profiles revealed sunitinib was associated with significant CA9 region loss. RNAi CA9 silencing in two cell lines inhibited the antiproliferative effects of sunitinib. Shortcomings of the study include selection of a specific protein for analysis, and the specific time points at which the treated tissue was analysed.ConclusionsCA9 levels increase with targeted therapy in mccRCC. Lower CA9 levels are associated with a poor prognosis and possible resistance, as indicated by the validation cohort.Patient summaryDrug treatment of advanced kidney cancer alters molecular markers of treatment resistance. Measuring carbonic anhydrase 9 levels may be helpful in determining which patients benefit from therapy
Transcriptomic mapping of integrins and immune activation in high-grade serous ovarian cancer
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
Personalised Therapeutic
- âŠ